RE:Rvv has big position in red light Holland symbol trip Relationship between RVV & RED LIGHT May 25, 2020 (Source) Red Light Holland Corp. (Red Light or the Company) is pleased to announce that the Canadian Securities Exchange (the CSE) provided the Company with conditional approval on May 22, 2020 to list its common shares (Common Shares). The Company is in the process of filing final documents with the CSE and, subject to satisfying customary listing conditions, expects the Common Shares to commence trading on May 28, 2020 under the ticker symbol TRIP (the CSE Listing).The Company is also pleased to report that its previously announced reverse takeover transaction (the RTO Transaction) with Red Light Holland Financing Inc. (Finco) and Red Light Holland Debt Inc. (Debtco) closed on May 22, 2020. The RTO Transaction was effected by way of two triangular amalgamations among (a) the Company, Debtco and a wholly-owned subsidiary of the Company, and (b) the Company, Finco and another wholly-owned subsidiary of the Company. The Company is a reporting issuer whose Common Shares were voluntarily delisted from the TSX Venture Exchange on May 23, 2019, and consequently have not been posted for trading on any marketplace since such that time.Following the CSE Listing, the Company, through one or more wholly-owned subsidiaries, intends to establish itself as a producer and distributor of its premium brand of psilocybin truffles (Truffles) within the Netherlands. By doing so, the Company hopes to contribute to the advancement and awareness of Truffles, and promote its potential as a candidate for further research and study. The Companys target market is focused on the recreational space, and includes young professionals, and socially and artistically conscious individuals who are part of the positive counterculture.In connection with the completion of the RTO Transaction, the board of directors and senior officers of the Company were reconstituted to consist of Todd Shapiro (Director, Chairman and Chief Executive Officer), Hans Derix (President), Kyle Appleby (Chief Financial Officer), Anne Barnes (Director), Lowell Kamin (Director), and Binyomin Posen (Director). Additional information regarding the business of the Company and the biographical details of the board of directors and senior officers can be found in the Companys CSE Form 2A Listing Statement, which will be filed on SEDAR prior to the commencement of trading of the Common Shares on the CSE.Completing the Canadian Securities Exchange listing is a key milestone for the Company, as Red Light Holland embarks on becoming a leading provider of Truffles for the legal recreational Truffles market said Todd Shapiro, the Chief Executive Officer and Chairman of the Company. Mr. Shapiro further commented fulfilling our commitment to become a publicly listed company will provide the Company with access to institutional capital to foster our development and expansion plans. We are very grateful to the Canadian Securities Exchange, its staff and all our services providers for assisting us in achieving this important milestone.In connection with the RTO Transaction, the escrowed portion of the net proceeds from the Companys previously announced private placement offering of subscription receipts of Finco (the Financing) were released from escrow and the subscription receipts were converted into 66,022,530 Common Shares. As a result of the completion of the RTO Transaction, former holders of subscription receipts from the Financing now hold approximately 34.06% of the Common Shares, on a non-diluted basis..----------------------------------------~~~~~~~----------------------------------------------~~~~~~~~~~~~~~~ Revive Therapeutics to Pursue the Psychedelic Market With Agreement and Investment in Red Light Holland Financing February 10, 2020 07:00 ET | Source: Revive Therapeutics Ltd. TORONTO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (Revive), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has entered into a supply and collaboration agreement (the Agreement) with Red Light Holland Financing Inc. (Red Light), an arms length party. Pursuant to the Agreement Red Light will sell to Revive a consistent strain of truffles for the sole purpose of Revive undertaking research and development on the suitability and implementation of its novel cannabinoid delivery technology with respect to the truffles and its extracts. Red Light has also agreed to, upon request, provide Revive with any information, studies, papers and other information it may have pertaining to the truffles which may be deemed to be beneficial to Revive for undertaking the research and development. Revive is excited to be working with Red Light to explore the use of its delivery technology with unique products such as truffles, stated Michael Frank, the President of Revive. We are confident that the results of Revives research will highlight the versatility of its cannabinoid delivery platform. As Red Light Holland heads down the road of securing its facility in the Netherlands and commencing our cultivation of Premium Red Light Truffles, we are elated to be partnering and eventually aiming to supply companies with our truffles, such as Revive, who will perform true clinical testing in hopes of publishing ground-breaking and progressive medical results, said Todd Shapiro, CEO of Red Light Holland. In addition, as a condition of the Agreement, Revive has agreed to subscribe for 2,500,000 subscription receipts (the Subscription Receipts) of Red Light at a price of $0.06 per Subscription Receipt for an aggregate consideration of $150,000. Each Subscription Receipt shall entitle Revive, upon conversion and with any additional consideration, to acquire one common share in the capital of Red Light. In consideration for the Subscription Receipts, Revive will issue to Red Light an aggregate of 3,000,000 common shares in the capital of Revive at a price of $0.05 per share for aggregate consideration of $150,000. About Red Light Holland Financing Inc. Red Lights core business is expected to revolve around the production, growth and sale of truffles products in compliance with all applicable laws and is a company registering, strategically, to be based in the Netherlands, an area that currently sells truffles. Red Light has collected a core group of highly skilled individuals who bring a wealth of knowledge and experience relating to growing, mass-producing, compliance, distributing, marketing and managing - which the company believes is necessary to assist in establishing itself as a leader in this emerging field. Red Light intends to fill this gap by providing a product that is grown under the strictest health and safety guidelines, and intends to market and sell its products pursuant to an EU-GMP certification, which it does not currently possess. Red Light plans to generate revenues by providing recreational grade truffles and potentially EU-GMP medical grade truffles to the current adult use market in the Netherlands. About Revive Therapeutics Ltd. Revive is a cannabis life sciences company focused on the research, development and commercialization of novel cannabinoid-based products. Revives novel cannabinoid delivery technology is being advanced to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Revives cannabinoid pharmaceutical portfolio focuses on rare inflammatory and liver diseases. For more information, visit www.ReviveThera.com.